Rami Alharethi, MD
Disclosures: Nothing to disclose

Rami Alharethi, MD FACC

Heart Failure Prevention & Treatment Program

Intermountain Medical Center

J.L Sorenson Heart & Lung Center LL1

5121 S Cottonwood St

Murray, UT 84107





1988-1995      Medical Diploma, Aleppo University, Faculty of Medicine, Aleppo, Syria


1996-1997             Research assistant, Brigham and Women’s Hospital, Boston, MA


1997-1998             Research Assistant, Massachusetts General Hospital, Boston, MA


1998-2001              Internal Medicine Residency, St. Joseph Hospital, Northwestern University, Chicago, IL


2001-2003             Heart Failure & Cardiac Transplantation Fellowship, University of Utah, Salt Lake City, UT


2003-2005             Cardiovascular Fellowship, University of Utah, Salt Lake City, UT





2005-2009             Assistant Professor of Medicine, Cardiovascular Division, Oregon Health & Science University, Portland, Oregon


2007-2009             Medical Director, Heart Failure & Cardiac Transplantation Program, Oregon Health & Science University, Portland, Oregon


2009-Present              Cardiology Director, mechanical circulatory support program, Intermountain Medical Center, Murray, UT


2009-2017              Assistant Medical Director, UTAH Cardiac Transplant Program, Intermountain Medical Center, Murray, UT


2012-Present              Adjunct Assistant Professor of Medicine, University of Utah, Salt Lake City, UT


2017-Present Medical Director, UTAH Cardiac Transplant Program, Intermountain Medical Center, Murray, UT



Honors & Awards


2007              Internal Medicine Teaching Award, Oregon Health & Science University, Portland, Oregon


2009                                 Internal Medicine Teaching Award, Oregon Health & Science University, Portland, Oregon





English, Arabic





2004                                 American Board of Cardiovascular Medicine


2010                          American Board of Advanced Heart Failure and Transplant Cardiology





State of Utah



Professional Societies


Heart Failure Society of America


International Society of Heart and Lung Transplantation


Fellow of American College of Cardiology





2007-2008              Principal Investigator: HF-Action: Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training. National Institutes of Health.


2008-2009              Principal Investigator: Telemonitoring to Improve Heart Failure Outcomes (Tele-HF). National Institutes of Health.


2009              Co-Principal Investigator: CUPID Trial-Calcium Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease.


2009              Co-Principal Investigator: CMV-Accelerated CR in Cardiac Transplant Recipients.


2009-2011                            Co-investigator, DIURETIC OPTIMIZATION STRATEGIES EVALUATOIN IN ACUTE HEART FAILURE (DOSE-AHF). National Institutes of Health.


2009-2012                            Co-investigator, PROTOCOL FOR THE CARDIORENAL RESCUE STUDY IN ACUTE DECOMPENSATED HEART FAILURE (CARESS-HF). National Institutes of Health.




2009-Present              Co-investigator, Genome-wide Associations with Peripartum Cardiomyopathy.


2009-Present              Principle Investigator, The Peripartum Cardiomyopathy Network.

              National Institutes of Health.


2010-2015              Principle Investigator, Left Atrial Pressure Monitoring to optimize Heart Failure Therapy Study (LAPTOP-HF).


2011-Present              Principle Investigator, Cardiac biomarker and Peripartum Cardiomyopathy (Intermountain Research and Medical Foundation grant 40,000.00$, Harold Burton Foundation 10,000.00$).


2011-2015              Co-Investigator, Prevention of Cardiac Allograft Vasculopathy Using Rituximab Therapy in Cardiac Transplantation. National Institutes of Health.


2012-2014              Principle Investigator, Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure.


2012-2013              Principle Investigator, Insulin growth Factor-1 and Cardiac Allograft Vasculopathy (Intermountain Research and Medical Foundation grant 8,196.00 $).


2016- Present              Principle investigator, Barostim Therapy for Heart Failure.


2017-Present              Principle investigator, A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)


2018-Present              Donor Derived Free Cell DNA and Cardiac Allograft Vasculopathy. (Intermountain Research and Medical Foundation grant 39,123.00$)





1.      Mason NO, Reid BB, Harmston G, Jones J, Stoker S, Budge D, Alharethi R, Thomsen G, Clayson SE, MD, Caine W, Kfoury AG. Characterization of Gastrointestinal Bleeding in HeartMate II Left Ventricular Assist Device Patients. J Heart Lung Transplant 2010;29(2S):S175.


2.      McCormick AJ, Reid BB, Budge D, Clayson SE, Stoker SL, Raymond AL, Smith HK, Doty JR, Caine WT, Alharethi RA, Kfoury AG. Versatility and Patient Outcomes with the Levitronix CentriMag Temporary Ventricular Assist Device. J Heart Lung Transplant 2010;29(2S):S100.


3.      Budge D, Khan F, Hammond MEH, Nilson ZD, Stehlik J, Alharethi RA, Everitt MD, Gilbert EM, Bader F, Miller DV, Revelo P, Drakos SG, MD, Kfoury AG. Safety and Outcomes with Newer Treatment Strategies for Cardiac Antibody-mediated Rejection: Still in the Woods. J Heart Lung Transplant 2010;29(2S):S42.


4.      Revelo MP, Miller DV, Kfoury AG, Stehlik J, Everitt MD, Budge D, Alharethi RA, Gilbert EM, Bader F, Hammond MEH. Longitudinal Evaluation of Microvessel Density in Survivors versus Non-survivors of Cardiac Antibody-mediated Rejection. J Heart Lung Transplant 2010;29(2S):S149.




5.      Nixon JL, Brunisholz K, Horne B, Myrick C, Budge D, Kfoury AG, Everitt M, Stehlik J, Schmidt TC, Gilbert EM, Bader F, Alharethi RA. Impact of high dose Inotropic Donor Support on Early Myocardial Necrosis and Outcome in Cardiac Transplantation. J Heart Lung Transplant 2010;29(2S):S167.


6.      Hammond MEH, Miller DV, Revelo MP, Stehlik J, Snow G, Everitt MD, Budge D, Alharethi RA, Gilbert EM, Bader F, Kfoury AG. What Are the Best Antibody Predictors of AMR Resulting in Cardiac Death? J Heart Lung Transplant 2010;29(2S):S38.


7.      Drakos SG, Hammond MEH, Reid BB, Stoker S, Revelo MP, Rasmusson B, Selzman C, Alharethi RA, McCormick A, Gilbert EM, Miller DV, Li D, Kfoury AG. Effect of Mechanical Unloading on Fibrosis and Hypertrophy during Cardiac Remodeling in Humans. J Heart Lung Transplant 2010;29(2S):S242.


8.      Everitt MD, Yetman AT, Donaldson AE, Stehlik J, Kaza AK, Budge D, Alharethi RA, Bullock EA, Cardon M, Tani LT, Kfoury AG. Does Access to Device Therapies Affect Transplant Outcomes for Adults with Congenital Heart Disease? Analysis of the United Network for Organ Sharing (UNOS) Database. J Heart Lung Transplant 2010;29(2S):S71.


9.      Ventura PA, Reid BB, Horne BD, Mason NO, Stoker SL, Alharethi RA, Budge D, Rasmusson B, Doty JR, Clayson SE, Kfoury AG. : Differential Impact on Post-transplant Outcomes between HeartMate XVE and HeartMate II Left Ventricular Assist Devices. J Heart Lung Transplant 2010;29(2S):S99.


10.  Shah SK, Verma DR, Snow G, Kfoury AG, Bader F, Brunisholz K, Drakos SG, ME Hammond, Revelo MP, Gilbert EM, Alharethi R, Budge D, Everitt MD, Selzman C, Stehlik J. Inhibition of Angiotensin Signaling Reduces Incidence of Antibody Mediated Allograft Rejection. J Am Coll Cardiol 2010;55(Suppl A):A19.


11.  Drakos S, Verma DR, Stehlik J, Kotter J, Selzman C, Reid B, Horne B, MD, Hammond E, Gilbert E, Alharethi R, Revelo MP, Kfoury AG. Impact of Cellular Blood Product Transfusions on the Incidence of Cardiac Allograft Rejection. Am J Transplant 2010;10(Suppl 4):A1276.


12.  Verma DR, Drakos SG, Revelo MP, Kfoury AG, Khan F, Hammond MEH, Bader F, Alharethi R, Gilbert EM, Budge D, Miller DV, Everitt MD, Stehlik J. Digital Histopathology Allows for Quantification of Capillary Loss in Cardiac Allograft Vasculopathy. Am J Transplant 2010;10(Suppl 4):A57.


13.  Horne BD, May HT, Muhlestein JB, Lappé DL, Budge D, Alharethi R, Carlquist JF, Kfoury AG, Anderson JL. Improvement beyond the Framingham Risk Score for prediction of mortality by the addition of the Intermountain Risk Score. J Am Coll Cardiol 2010;55(Suppl A);A134.


14.  Mason NO, Sorenson M, Johnson D, Young S, Reid BB, Stoker S, Alharethi R, Budge D, Rasmusson B, Kfoury AG. “Characterization of Reasons for Turning down Referrals for Left Ventricular Assist Devices (LVADs)” (ASAIO 2010)


15.  Ventura PA, Mason NO, McCormick A, Ledford I, Reid B, Budge D, Alharethi R, Stoker S, Smith H, Kfoury AG. “Outcomes with the Levitronix CentriMag as Cardiopulmonary Support (CPS) for Cardiogenic Shock” (ASAIO 2010)


16.  McCormick AJ, Ledford ID, Mason NO, Reid BB, Clayson SE, Alharethi R, Stoker S, Budge D, Kfoury AG. “Time-Dependent Differences in the Cause of Death after Left Ventricular Assist Device Implantation” (ASAIO 2010)


17.  Ledford ID, McCormick AJ, Mason NO, Ventura PA, Reid BB, Rasmusson BY, Budge D, Stoker S, Kfoury AG, Alharethi R. “Clinical Predictors for Long Hospital Stay after Left Ventricular Assist Device (LVAD) Implantation” (ASAIO 2010)


18.  Rasmusson K, Budge D, Alharethi R, Brunisholz K, Connolly J, Jensen K, Horne B, Endo M, Stehlik J, Kfoury A. “Long-term Outcomes in Patients with Peripartum Cardiomyopathy and no Recovery of Ventricular Function” (HFSA 2010)


19.  Rasmusson K, Alharethi R, Budge D, Brunisholz K, Horne B, Connolly J, Jensen K, Stehlik J, Kfoury A. : “Peripartum Cardiomyopathy: Echocardiographic Characteristics and Medication use in Patients with versus without Recovery of Ventricular Function” (HFSA 2010)

20.  Rasmusson K, James B, Budge D, Alharethi R, Horne B, Lappé D, Connolly J, Roberts C, Simpson S, Kfoury A. “Sustained 5-year Survival Benefit with Heart failure Discharge Instructions” (HFSA 2010)


21.  Horne BD, Rasmusson KD, Alharethi RA, Budge D, Brunisholz KD, Carlquist JF, Connolly JJ, Porter TF, Park JJ, Lappé DL, Muhlestein JB, May HT, Bair TL, Anderson JL, Renlund DG, Kfoury AG. “Replication of Genome-wide Association of the PTHLH-KLHDC5 Locus with Peripartum Cardiomyopathy” (HFSA 2010)


22.  I.D. Ledford, D.V. Miller, N.O. Mason, R.A. Alharethi, B.Y. Rasmusson, D. Budge, S.L. Stoker, S.E. Clayson, J.R. Doty, G.E. Thomsen, W.T. Caine, A.G Kfoury, B.B. Reid. “Differential Infection Rates between Velour Versus Silicone Interface at the HeartMate II Driveline Exit Site: Structural and Ultrastructural Insight into Possible Causes. J Heart Lung Transplant 2011 Apr:40 (4S): S10-S11


23.  M.P. Revelo,  D. Budge, D.V. Miller, K.D. Brunisholz, T.L. Bair, M.E.Hammond, G.L. Snow, J. Stehlik, E.M. Gilbert, M.D. Everitt, R.A. Alharethi, A.G. Kfoury. “Microvessel Density in Cardiac Allograft Biopsies of Patients with Clinically Significant Coronary Allograft Vasculopathy”.  J Heart Lung Transplant 2011 Apr:40 (4S). S18.


24.  A.G. Kfoury, J.J. Connelly, G.L. Snow, D. Budge, D.V. Miller, F.M. Bader, R.A. Alharethi, J. Stehlik, B.B. Reid, M.D. Everitt, M.P. Revelo, E.M. Gilbert, C.H. Selzman, M.E.H. Hammond. “A Longitudinal Study of the Course of Untreated Antibody-Mediated Rejection in Heart Transplantation”. J Heart Lung Transplant 2011 Apr:40 (4S). S40-S41.





25.  K.D. Brunisholz, A.G. Kfoury, E.M. Gilbert, R. Alharethi, J.L. Anderson, J. Stehlik, D. Budge, S.G. Drakos, D.R. Verma, A. Saidi, K.D. Balling, J.W. Folsom, D.L. Lappé, K.D. Rasmusson, F.M. Bader, B.D. Horne . “The Intermountain Risk Score Predicts Post-Transplant Survival When Calculated from Pre-Transplant Clinical Laboratory Values”. J Heart Lung Transplant 2011 Apr:40 (4S). S47.


26.  O. Wever Pinzon, G.J. Stoddard, F. Bader, S. Drakos, C. Selzman, D. Budge, R. Alharethi, J. Nativi, E. Gilbert, A. Kfoury, M. Everitt, J. Stehlik. “Impact of Donor Left Ventricular Hypertrophy on Cardiac Transplant Recipients Outcomes”. J Heart Lung Transplant 2011 Apr:40 (4S). S67-S68.


27.  D.R. Verma, S.G. Drakos, K. Brunisholz, G. Snow, D. Budge, J. Stehlik, C.H. Selzman, M. Eidson, D.V. Miller, R. Alharethi, F. Bader, B.B. Reid, M.P. Revelo, E.M. Gilbert, A.G. Kfoury “Antibody-Mediated Rejection in Patients Bridged to Heart Transplantation with Mechanical Circulatory Support” J Heart Lung Transplant 2011 Apr:40 (4S). S88


28.  M.P. Revelo, D.V. Miller, A.G. Kfoury, J. Stehlik, M. Everitt, D. Budge,
R. Alharethi, E.M. Gilbert, F. Bader, M.E.H. Hammond. “Longitudinal valuation of Microvessel Density in Survivors Versus Non-Survivors of Cardiac Anti-body-Mediated Rejection” J Heart Lung Transplant 2011 Apr:40 (4S). S149


29.  J.N. Nativi, G. Stoddard, S. Drakos, E.M. Gilbert, F. Bader, A.G. Kfoury, D. Budge, R. Alharethi, C. Selzman, M. Everitt, J. Stehlik. “Changing Patterns in the Utilization of Cardiac Allografts – Is it Time To Abandon the High-risk Donor? An Analysis of the U.S.Scientific Registry of Transplant Recipients”         J Heart Lung Transplant 2011 Apr:40 (4S).  S69-S70


30.  D. Budge, K.D. Brunisholz, O. Pinzon, S.M. Belleville, R.A Alharethi, J. Stehlik, M.P. Revelo, M.D. Everitt, M.E.H. Hammond, E.M. Gilbert D.V. Miller, F.M. Bader, K.M. Molina, A.G. Kfoury. “Is a high AlloMap® Score in the Absence of Cellular Rejection Associated with Antibody-Mediated Rejection?” J Heart Lung Transplant 2011 Apr:40 (4S). S101


31.  S.P. McCandless, J.R. Revenaugh, A.G. Kfoury, B.B. Reid, D. Budge, J.R. Doty, S. Stoker, S.E. Clayson, R.A. Merchel, H.K. Smith, I.D. Ledford, M. Goddard, P.A. Ventura, W.T. Caine, R. Alharethi. “The Versatility and Outcomes for Patients with TandemHeart® Temporary Ventricular Assist Device Support”         J Heart Lung Transplant 2011 Apr:40 (4S). S160


32.  M.P. Revelo, J.L. Nixon, D.V. Miller, K.D. Brunisholz, T.L. Blair,
M.E.H Hammond, G.L. Snow, J. Stehlik, E.M.L. Gilbert, R.A. Alharethi, D. Budge, M.D. Everitt, A.G. Kfoury. “Microvessel Density in Cardiac Allograft Biopsies in Patients with Clinically Significant Coronary Allograft Vasculopathy Treated with Sirolimus” J Heart Lung Transplant 2011 Apr:40 (4S). S172


33.  F. Isaac, D. Miller, M.P. Revelo, M.E.H. Hammond, J.W. Folsom, E.M. Gilbert, J. Stehlik, F.M. Bader, R.A. Alharethi, M.D. Everitt, A.G. Kfoury. “The role of Post-Mortem Examination in a Cardiac Transplant Program: Lessons from 101 Autopsies over 25 years at Utah Transplant Affiliated Hospitals”  J Heart Lung Transplant 2011 Apr:40 (4S). S172-173

34.  S.G. Drakos, D.R. Varma, G.L. Snow, A. Saidi, K. Brunisholz, M.E.H. Hammond, R.A. Alharethi, J. Stehlik, M.D. Everitt, E.M. Gilbert, M.P. Revelo, D. Budge, D.V. Miller, A.G. Kfoury. “Does Immune System Activation from Cellular Rejection Trigger Antibody-Mediated Rejection in Heart Transplantation?” J Heart Lung Transplant 2011 Apr:40 (4S). S175

35.  S.G. Drakos, D.R. Verma, O.M. Abdulla,  A.G. Kfoury,  J. Stehlik, C.H. Selzman, B.B. Reid, E.M. Gilbert, R. Alharethi, C. Myrick, D. Budge, G. Russel, S. Clayson, D. Bull, E.H. Hammond, E Hsu, D.Y. Li. “Characterization of the Failing Human Heart Via Diffusion Tensor Imaging: An Ex-Vivo Study” J Heart Lung Transplant 2011 Apr:40 (4S).  S189


36.  A. Saidi, J. Stehlik, A.G. Kfoury, K.D. Brunisholz, F. Khan, D. Budge, S. Drakos, M.D. Everitt, C. Selzman, E.M. Gilbert, B.B. Reid, F.M. Bader, R. Alharethi. “Impact of Sildenadfil Therapy on Heart Transplant Recipients with Non-Reversible Pulmonary Hypertension”.  J Heart Lung Transplant 2011 Apr:40 (4S). S192-S193


37.  S.G. Drakos, D.R. Verma, B.B. Reid, J. Stehlik, E.M. Gilbert, C.H. Selzman, D. Budge, M. Yilmazer, K. Horton, B. Rasmusson, F. Bader, S. Clayson, A. Saidi, D. Bull, D.Y. Li, A.G. Kfoury, R. Alharethi. “Mechanical Unloading with Continuous-Flow Left Ventricular Assist Devices: Affects on Left Atrial  Remodeling” J Heart Lung Transplant 2011 Apr:40 (4S). S215





  1. Alharethi R, Moussa A, "Congestive Heart Failure; Causes and Treatment” Elrehawi Publishing 1994.


  1. Samer Jabbour, Susanna Bedell, Rami Alharethi, Robert Goldberg “Management of Hyperglycemia and Diabetes in Outpatient Cardiology Practice” Cardiology 2002;97,183-186.


  1. Movesesian MA, Alharethi R “Inhibitors of cyclic nucleotide phosphodiesterase PDE3 a adjunct therapy for dilated cardiomyopathy” Expert Opin Investig Drugs 2002 Nov; 11(11)1529-1536.


  1. Alharethi R, Shaddy RE, Doty DB, Moore SA, Hammond EH, Dabbas B, Fuller TC, Renlund DG “ Early Failure of a Tricuspid Valve Replacement with a Mitral Valve Homograft in a Heart transplant Recipient” J Heart Lung Transplant. 2004 Dec;23(12):1460-2.


  1. John R. Bullinga, MD, Rami Alharethi, MD, Mark S. Schram, MD, FACC,  Michael R. Bristow, MD, PhD, Edward M. Gilbert, MD, FACC.  “Changes in Heart Rate Variability correlated to Hemodynamic Improvement with Chronic Carvedilol Therapy in Heart Failure” J Card Fail. 2005 Dec;11(9):693-9.


  1. Rami Alharethi, MD; Feras Bader, MD; Abdallah G Kfoury, MD; M. Elizabeth H Hammond, MD; Shreekanth V Karwande, MD; Edward M Gilbert, MD; Donald B Doty, MD; Mary E Hagan, MSFNP; Heidi Thomas, MS; Dale G Renlund, MD “Tricuspid Valve Replacement after Cardiac Transplantation”  J Heart Lung Transplant. 2006;25:48-52.
  2. May HT, Alharethi R, Anderson JL, Muhlestein JB, Reyna SP, Bair TL, Horne BD, Kfoury AG, Carlquist JF, Renlund DG “Homocysteine Levels Are Associated with Increased Risk of Congestive Heart Failure in Patients with and without Coronary Artery Disease”. Cardiology. 2006 Aug 28;107(3):178-184.


  1. Alharethi R, Hershberger RE. “Beta-blocker use in decompensated heart failure” Curr Heart Fail Rep. 2006 Jun;3(2):75-80.


  1. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008 Sep;295(3):H1234-H1242.


  1. Raymond AL, Kfoury AG, Bishop CJ, Davis ES, Goebel KM, Stoker S, Selzman CH, Clayson SE, Smith H, Cowley CG, Alharethi R, Budge D, Reid BB “Obesity and left ventricular assist device driveline exit site infection” . ASAIO J. 2010 Jan-Feb;56(1):57-60.


  1. Brush S, Budge D, Alharethi R, McCormick AJ, MacPherson JE, Reid BB, Ledford ID, Smith HK, Stoker S, Clayson SE, Doty JR, Caine WT, Drakos S, Kfoury AG. End-of-life decision making and implementation in recipients of a destination left ventricular assist device. J Heart Lung Transplant. 2010 Dec;29(12):1337-41.


  1. Revelo MP, Stehlik J, Miller D, Snow GL, Everitt MD, Budge D, Bader FM, Alharethi R, Gilbert EM, Reid BB, Selzman CH, Hammond ME, Kfoury AG. Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death?J Heart Lung Transplant. 2011 Feb;30(2):144-50.


  1. Everitt MD, Donaldson AE, Stehlik J, Kaza AK, Budge D, Alharethi R, Bullock EA, Kfoury AG, Yetman AT Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS). J Heart Lung Transplant. 2011 Apr;30(4):395-401.


  1. Ventura PA, Alharethi R, Budge D, Reid BB, Horne BD, Mason NO, Stoker S, Caine WT, Rasmusson B, Doty J, Clayson SE, Kfoury AG. “Differential impact on post-transplant outcomes between pulsatile- and continuous-flow left ventricular assist devices”. Clin Transplant 2011 Mar 14.


  1. Horne BD, Rasmusson KD, Alharethi R, Budge D, Brunisholz KD, Metz T, Carlquist JF, Connolly JJ, Porter TF, Lappé DL, Muhlestein JB, Silver R, Stehlik J, Park JJ, May HT, Bair TL, Anderson JL, Renlund DG, Kfoury AG. Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet. 2011 Aug 1;4(4):359-66.


  1. Lappé JM, Horne BD, Shah SH, May HT, Muhlestein JB, Lappé DL, Kfoury AG, Carlquist JF, Budge D, Alharethi R, Bair TL, Kraus WE, Anderson JL. Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clin Chim Acta. 2011 Nov 20;412(23-24):2094-9.
  2. Healy AH, Mason NO, Hammond ME, Reid BB, Clayson SE, Drakos SG, Kfoury AG, Patel AN, Bull DA, Budge D, Alharethi RA, Bader FM, Gilbert EM, Stehlik J, Selzman CH. Allograft rejection in patients supported with continuous-flow left ventricular assist devices. Ann Thorac Surg. 2011 Nov;92(5):1601-7.


  1. Nixon JL, Kfoury AG, Brunisholz K, Horne BD, Myrick C, Miller DV, Budge D, Bader F, Everitt M, Saidi A, Stehlik J, Schmidt TC, Alharethi R. Impact of high-dose inotropic donor support on early myocardial necrosis and outcomes in cardiac transplantation. Clin Transplant 2012 Mar-Apr;26(2):322-7


  1. Horne BD, Muhlestein JB, Lappé DL, Brunisholz KD, May HT, Kfoury AG, Carlquist JF, Alharethi R, Budge D, Whisenant BK, Bunch TJ, Ronnow BS, Rasmusson KD, Bair TL, Jensen KR, Anderson JL. The intermountain risk score predicts incremental age-specific long-term survival and life expectancy. Transl Res. 2011 Nov;158(5):307-14


  1. Saidi A, Alharethi R. Management of chemotherapy induced cardiomyopathy. Curr Cardiol Rev. 2011 Nov 1;7(4):245-9.


  1. Revelo MP, Miller DV, Stehlik J, Brunisholz K, Drakos S, Gilbert EM, Everitt M, Budge D, Alharethi R, Snow G, Hammond EH, Kfoury AG. Longitudinal evaluation of microvessel density in survivors vs nonsurvivors of cardiac pathologic antibody-mediated rejection. Cardiovasc Pathol. 2012 Feb 28.


  1. Rasmusson K, Brunisholz K, Budge D, Horne BD, Alharethi R, Folsom J, Connolly JJ, Stehlik J, Kfoury A. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant. 2012 Feb; 31 (2) :180-6.


  1. Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, Miller DV, Drakos SG, Reid BB, Revelo MP, Gilbert EM, Selzman CH, Bader FM, Connelly JJ, Hammond ME. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2012 Jan; 31 (1) :46-51.


  1. Gupta A, Braunwald E, McNulty S, Felker GM, Gilbert EM, Alharethi R, Lee KL, Anstrom KJ, Redfield MM, Goldsmith SR, O'Connor CM, Bull DA, Stehlik J, Litwin SE. Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. J Card Fail. 2012 Nov;18(11):837-44.


  1. Horne BD, Lappé DL, Muhlestein JB, May HT, Ronnow BS, Brunisholz KD, Kfoury AG, Bunch TJ, Alharethi R, Budge D, Whisenant BK, Bair TL, Jensen KR, Anderson JL. Repeated measurement of the intermountain risk score enhances prognostication for mortality. PLoS One. 2013;8(7).


  1. Januzzi JL, Horne BD, Moore SA, Galenko O, Snow GL, Brunisholz KD, Muhlestein JB, Alharethi R, Carlquist JF, Budge D, Rasmussen K, Kfoury AG. Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers. 2013 May;18(3):250-6.



  1. Wever-Pinzon O, Drakos SG, Kfoury AG, Nativi JN, Gilbert EM, Everitt M, Alharethi R, Brunisholz K, Bader FM, Li DY, Selzman CH, Stehlik J. Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified?. Circulation. 2013 Jan 29;127(4):452-62.


  1. Labedi MR, Alharethi R, Kfoury AG, Budge D, Bruce R, Rasmusson B, Bunch TJ. Electromagnetic interference of automatic implantable cardioverter defibrillator and HeartWare left ventricular assist device. ASAIO J. 2013 Mar-Apr;59(2):136-9.


  1. Drakos SG, Wever-Pinzon O, Selzman CH, Gilbert EM, Alharethi R, Reid BB, Saidi A, Diakos NA, Stoker S, Davis ES, Movsesian M, Li DY, Stehlik J, Kfoury AG, UCAR (Utah Cardiac Recovery Program) Investigators. Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol. 2013 May 14;61(19):1985-94.


  1. Alharethi R. Cardiovascular involvements in HIV-infected patients. Expert Rev Cardiovasc Ther. 2013 Sep;11(9):1227-35.


  1. Alsamara M, Alharethi R. Heart Failure with Preserved Ejection Fraction. Expert Rev Cardiovasc Ther. 2014 Jun;12(6):743-50.


  1. Nixon JL, Kfoury AG, McCubrey R, Brunisholz K, Bair T, Balling KD, Budge D, Doty J, Rasmusson B, Reid B, Smith H, Thomsen G, Goddard M, Alharethi R. Lactic acidosis after cardiac transplantation: foe or common innocent bystander? Transplantation. 2015 Jun;99(6):1216-9


  1. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, Modi K, Alexis JD, Ramani GV, Semigran MJ, Haythe J, Markham DW, Marek J, Gorcsan J 3rd, Wu WC, Lin Y, Halder I, Pisarcik J, Cooper LT, Fett JD; IPAC Investigators. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 Aug 25;66(8):905


  1. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker-Kleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J, Hanley-Yanez K, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Kealey A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V, Zucker MJ, Liu P, Gorcsan J 3rd, McNamara DM, Seidman CE, Seidman JG, Arany Z; IMAC-2 and IPAC Investigators. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016 Jan 21;374(3):233-41.


  1. Kfoury AG, Miller DV, Snow GL, Afshar K, Stehlik J, Drakos SG, Budge D, Fang JC, Revelo MP, Alharethi R, Gilbert EM, Caine WT, McKellar S, Molina KM, Hammond ME. Mixed cellular and antibody-mediated rejection in heart transplantation: In-depth pathologic and clinical observations. J Heart Lung Transplant. 2016 Mar; 35(3):335-41.


  1. Johnson AK, McCandless SP, Alharethi R, Caine WT, Budge D, Wright GA, Rauf A, Miller A, Stoker S, Smith H, Afshar K, Reid BB, Rasmusson BY, Kfoury AG. Reasons for, and outcomes of patients who were referred for a ventricular assist device but were declined: the recent era forgotten ones. Clin Transplant. 2016 Mar;30(3):195-201.



  1. Damp J, Givertz MM, Semigran M, Alharethi R, Ewald G, Felker GM, Bozkurt B, Boehmer J, Haythe J, Skopicki H, Hanley-Yanez K, Pisarcik J, Halder I, Gorcsan J 3rd, Rana S, Arany Z, Fett JD, McNamara DM; IPAC Investigators. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. JACC Heart Fail. 2016 May;4(5):380-8.


  1. Blauwet LA, Delgado-Montero A, Ryo K, Marek JJ, Alharethi R, Mather PJ, Modi K, Sheppard R, Thohan V, Pisarcik J, McNamara DM, Gorcsan J 3rd; IPAC Investigators*. Right Ventricular Function in Peripartum Cardiomyopathy at Presentation Is Associated With Subsequent Left Ventricular Recovery and Clinical Outcomes. Circ Heart Fail. 2016 May;9(5).


  1. Ko BS, Drakos S, Kfoury AG, Hurst D, Stoddard GJ, Willis CA, Delgado JC, Hammond EH, Gilbert EM, Alharethi R, Revelo MP, Nativi-Nicolau J, Reid BB, McKellar SH, Wever-Pinzon O, Miller DV, Eckels DD, Fang JC, Selzman CH, Stehlik J; Utah Transplant Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant. J Heart Lung Transplant. 2016 Aug;35(8):1024-30.


  1. Risk score-guided multidisciplinary team-based Care for Heart Failure Inpatients is associated with lower 30-day readmission and lower 30-day mortality.

Horne BD, Roberts CA, Rasmusson KD, Buckway J, Alharethi R, Cruz J, Evans RS, Lloyd JF, Bair TL, Kfoury AG, Lappé DL. Am Heart J. 2019 Sep 11;219:78-88. 


  1. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study. Khush KK, Patel J, Pinney S, Kao A, Alharethi R, DePasquale E, Ewald G, Berman P, Kanwar M, Hiller D, Yee JP11, Woodward RN, Hall S, Kobashigawa J. Am J Transplant. 2019 Oct;19(10):2889-2899.